The IVS4+4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients

被引:52
作者
Futaki, M
Yamashita, T
Yagasaki, H
Toda, T
Yabe, M
Kato, S
Asano, S
Nakahata, T
机构
[1] Univ Tokyo, Inst Med Sci, Dept Hematol Oncol, Minato Ku, Tokyo 1088639, Japan
[2] Univ Tokyo, Inst Med Sci, Dept Pediat, Minato Ku, Tokyo 1088639, Japan
[3] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Med, Tokyo 1088639, Japan
[4] Tokai Univ, Sch Med, Dept Pediat, Isehara, Kanagawa 25911, Japan
关键词
D O I
10.1182/blood.V95.4.1493.004k35_1493_1498
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fanconi anemia (FA) is an autosomal recessive disease characterized by congenital anomalies, aplastic anemia, and a susceptibility to leukemia. There are at least 8 complementation groups (A through H), Extensive analyses of the FA group C gene FANCC in Western countries revealed that 10% to 15% of FA patients have mutations of this gene. The most common mutation is IVS4 + 4A to T (IVS4), a splice mutation in intron 4, which has been found only in patients of Ashkenazi Jewish ancestry. When we screened 29 Japanese patients (20 unrelated patients and 4 families) using polymerase chain reaction-single strand conformation polymorphism, we found 8 unrelated patients homozygous for IVS4. This is apparently the first non-Ashkenazi-Jewish population for whom this mutation has been detected. The Ashkenazi Jewish patients homozygous for IVS4 have a severe phenotype, in comparison with other FA patients. Our analyses of Japanese patients indicate no significant difference between IVS4 homozygotes and other patients with regard to severity of a clinical phenotype. Thus, ethnic background may have a significant effect on a clinical phenotype in FA patients carrying the same mutation. (C) 2000 by The American Society of Hematology.
引用
收藏
页码:1493 / 1498
页数:6
相关论文
共 39 条
[1]   FANCONI-ANEMIA AND ITS VARIABILITY [J].
ALTER, BP .
BRITISH JOURNAL OF HAEMATOLOGY, 1993, 85 (01) :9-14
[2]   Positional cloning of the Fanconi anaemia group A gene [J].
Apostolou, S ;
Whitmore, SA ;
Crawford, J ;
Lennon, G ;
Sutherland, GR ;
Callen, DF ;
Ianzano, L ;
Savino, M ;
DApolito, M ;
Notarangelo, A ;
Memeo, E ;
Piemontese, MR ;
Zelante, L ;
Savoia, A ;
Gibson, RA ;
Tipping, AJ ;
Morgan, NV ;
Hassock, S ;
Jansen, S ;
deRavel, TJ ;
VanBerkel, C ;
Pronk, JC ;
Easton, DF ;
Mathew, CG ;
Levran, O ;
Verlander, PC ;
Batish, SD ;
Erlich, T ;
Auerbach, AD ;
CletonJansen, AM ;
Moerland, EW ;
Cornelisse, CJ ;
Doggett, NA ;
Deaven, LL ;
Moyzis, RK .
NATURE GENETICS, 1996, 14 (03) :324-328
[3]  
AUERBACH AD, 1989, BLOOD, V73, P39
[4]  
DAHL N, 1990, AM J HUM GENET, V47, P275
[5]   Fanconi anaemia forges a novel pathway [J].
DAndrea, AD .
NATURE GENETICS, 1996, 14 (03) :240-242
[6]   Molecular biology of Fanconi anemia: Implications for diagnosis and therapy [J].
DAndrea, AD ;
Grompe, M .
BLOOD, 1997, 90 (05) :1725-1736
[7]   The Fanconi anaemia group G gene FANCG is identical with XRCC9 [J].
de Winter, JP ;
Waisfisz, Q ;
Rooimans, MA ;
van Berkel, CGM ;
Bosnoyan-Collins, L ;
Alon, N ;
Carreau, M ;
Bender, O ;
Demuth, I ;
Schindler, D ;
Pronk, JC ;
Arwert, F ;
Hoehn, H ;
Digweed, M ;
Buchwald, M ;
Joenje, H .
NATURE GENETICS, 1998, 20 (03) :281-283
[8]   ANALYSIS OF 133 MEIOSES PLACES THE GENES FOR NEVOID BASAL-CELL CARCINOMA (GORLIN)-SYNDROME AND FANCONI-ANEMIA GROUP-C IN A 2.6-CM INTERVAL AND CONTRIBUTES TO THE FINE MAP OF 9Q22.3 [J].
FARNDON, PA ;
MORRIS, DJ ;
HARDY, C ;
MCCONVILLE, CM ;
WEISSENBACH, J ;
KILPATRICK, MW ;
REIS, A .
GENOMICS, 1994, 23 (02) :486-489
[9]  
Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866
[10]  
Gibson RA, 1996, HUM MUTAT, V8, P140, DOI 10.1002/(SICI)1098-1004(1996)8:2<140::AID-HUMU6>3.0.CO